ストックスクリーナーアプリを入手
1.44
3.21%
0.04
Medicinova Inc (MNOV) 最新ニュース
Is MediciNova Inc. stock a dividend growth opportunityPortfolio Return Summary & Reliable Price Breakout Signals - ulpravda.ru
MediciNova (NASDAQ:MNOV) Rating Increased to Strong-Buy at Lucid Cap Mkts - MarketBeat
MediciNova, Inc. Provides Shareholder Update on Clinical Trials and Strategic Developments for 2026 - Quiver Quantitative
2026 New Year’s Greetings from the CEO - The Manila Times
MediciNova (NASDAQ:MNOV) Shares Cross Above Two Hundred Day Moving Average – What’s Next? - Defense World
MNOVProspectus Filed Pursuant to Rule 424(b)(5) (424b5) - ADVFN
Retail Trends: Is MediciNova Inc stock a top pick in earnings seasonWeekly Profit Recap & High Conviction Buy Zone Picks - moha.gov.vn
4875.T Jumps 8.7% Today: Positive Momentum in Biotech - Meyka
MediciNova enters $50 million equity distribution agreement with Lucid Capital - Investing.com Nigeria
MediciNova Inc enters $50 million equity distribution agreement with Lucid Capital Markets - MarketScreener
Medicinova IncOn Dec 29, Entered $50 Million Equity Distribution Agreement With Lucid Capital Markets- SEC Filing - TradingView — Track All Markets
MediciNova Establishes Flexible At-The-Market Equity Program - TipRanks
MediciNova enters $50 million equity distribution agreement with Lucid Capital By Investing.com - Investing.com South Africa
MediciNova Signs Equity Distribution Agreement With Lucid Capital Markets - TradingView — Track All Markets
Form 424B5 MEDICINOVA INC - StreetInsider
MediciNova, Inc. (NASDAQ:MNOV) Sees Large Decline in Short Interest - MarketBeat
Bank Watch: Why MediciNova Inc. stock could benefit from AI revolutionTrade Analysis Report & AI Driven Stock Price Forecasts - moha.gov.vn
Is MediciNova Inc. stock a top pick in earnings seasonWeekly Investment Summary & Growth Focused Entry Point Reports - Bölüm Sonu Canavarı
Why MediciNova Inc. stock could benefit from AI revolutionQuarterly Portfolio Summary & Verified Technical Trade Signals - Улправда
Will MediciNova Inc. stock outperform value stocksDollar Strength & Real-Time Stock Movement Alerts - DonanımHaber
MediciNova (NASDAQ:MNOV) Receives Buy Rating from D. Boral Capital - Defense World
After-Hours Biotech Rally: Inspira, MediciNova, DiaMedica Therapeutics Among Gainers - Nasdaq
Aug Swings: Why MediciNova Inc. stock could benefit from AI revolution2025 Technical Overview & Verified Short-Term Plans - Улправда
D. Boral Capital Maintains MediciNova (MNOV) Buy Recommendation - Nasdaq
How MediciNova Inc. stock performs in rising dollar environmentEarnings Performance Report & Community Shared Stock Ideas - Улправда
MediciNova completes enrollment in chemotherapy neuropathy trial By Investing.com - Investing.com Nigeria
MNOV: Analyst Jason Kolbert Maintains 'Buy' Rating with $9 Price - GuruFocus
D. Boral Capital Reaffirms Buy Rating for MediciNova (NASDAQ:MNOV) - MarketBeat
MediciNova Completes Enrollment in a Phase 2 Study of Colorectal Cancer Drug - marketscreener.com
MediciNova completes enrollment in chemotherapy neuropathy trial - Investing.com India
MediciNova, Inc. Completes Patient Enrollment in Phase 2 OXTOX Study for MN-166 in Metastatic Colorectal Cancer Patients - Quiver Quantitative
MediciNova Announces Completion of Patient Enrollment - GlobeNewswire
Bank Watch: Will MediciNova Inc stock beat EPS estimatesJuly 2025 Breakouts & Community Driven Trade Alerts - moha.gov.vn
MediciNova (NASDAQ:MNOV) Stock Crosses Above 200-Day Moving Average – Here’s What Happened - Defense World
MediciNova (NASDAQ:MNOV) Stock Crosses Above 200-Day Moving AverageHere's What Happened - MarketBeat
Free cash flow per share of MediciNova, Inc. – TSE:4875 - TradingView — Track All Markets
MediciNova (NASDAQ:MNOV) Receives “Buy” Rating from D. Boral Capital - Defense World
MediciNova (MNOV) Analyst Rating Maintained at 'Buy' with $9.00 - GuruFocus
MediciNova completes enrollment in phase 2b/3 ALS clinical trial - Investing.com
MediciNova Provides Update on COMBAT-ALS Study of MN-166 for Amyotrophic Lateral Sclerosis - Quiver Quantitative
MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND - The Manila Times
MediciNova completes enrollment in phase 2b/3 ALS clinical trial By Investing.com - Investing.com UK
MediciNova (NASDAQ: MNOV) fully enrolls 234-patient Phase 2b/3 ALS ALS trial, targets 2026 top-line data - Stock Titan
Is MediciNova Inc a good long term investmentTake Profit Strategies & Ride the Wave of Market-Beating Growth - earlytimes.in
Gainers Report: Can MediciNova Inc stock continue upward trendShare Buyback & Growth Focused Investment Plans - BỘ NỘI VỤ
Can MediciNova Inc. stock sustain free cash flow growthMarket Volume Report & Free Weekly Chart Analysis and Trade Guides - Newser
EBITDA per share of MediciNova, Inc. – TSE:4875 - TradingView
Can MediciNova Inc. stock continue upward trendJuly 2025 Price Swings & Verified Entry Point Signals - Newser
MediciNova (MNOV) Stock Analysis Report | Financials & Insights - Benzinga
MediciNova (NASDAQ:MNOV) Stock Crosses Above 200-Day Moving Average – Should You Sell? - Defense World
MediciNova, Inc. (MNOV) 9.22% in After-hours: Amid Routine Trading - Stocks Telegraph
MediciNova Reports Significant Milestone in MN-001 Program Following Journal Publication on Cholesterol Efflux Mechanism - Quiver Quantitative
Message from the CEO to MediciNova Shareholders - GlobeNewswire
5.77%
大文字化:
|
ボリューム (24 時間):